RVMDW in the 13F filings
Revolution Medicines Inc · CUSIP 76155X118
- Quarter end
- 30 Sep 2026
- the date the book describes
- Filed
- 16 Nov 2026
- latest of these filings; the earliest 16 Nov 2026
- Managers listing it
- 3
- at least, of 95 tracked, among listed positions
- Comparable managers
- 46
- filed both Q2 2026 and Q3 2026; 1 listed it in both
- Shares listed
- 1,465,958
- combined, among listed positions
- Reported value
- $17m
- combined, at the quarter end
Among the 89 comparable managers: 0 buyers (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -814,022.
Managers listing RVMDW in Q3 2026
3 of 3 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| D. E. Shaw & Co. | 766,324 | $8.8m | under 0.1% | Trimmed | -814,021 | 16 Nov 2026 (the filing on sec.gov) |
| T. Rowe Price Associates Inc | 579,549 | $6.6m | under 0.1% | Trimmed | -1 | 16 Nov 2026 (the filing on sec.gov) |
| Farallon Capital Management LLC | 120,085 | $1.4m | under 0.1% | Held | 0 | 16 Nov 2026 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
No increase among listed positions.
Reductions
- D. E. Shaw & Co.existing position · 766,324 shares now-814,021
- T. Rowe Price Associates Incexisting position · 579,549 shares now-1
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2023 | 2 | $90k | 2 | 0 |
| Q1 2024 | 2 | $47k | 0 | 0 |
| Q2 2024 | 2 | $20k | 0 | 0 |
| Q3 2024 | 2 | $38k | 0 | 0 |
| Q4 2024 | 2 | $46k | 0 | 0 |
| Q1 2025 | 2 | $11k | 0 | 0 |
| Q2 2025 | 2 | $71k | 0 | 0 |
| Q3 2025 | 2 | $81k | 0 | 0 |
| Q4 2025 | 2 | $254k | 1 | 1 |
| Q1 2026 | 2 | $470k | 1 | 2 |
| Q2 2026 | 1 | $1.1m | 0 | 1 |
| Q3 2026 | 1 | $1.4m | 0 | 2 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
RVMDW and GILD →RVMDW and AMGN →RVMDW and MRNA →Choose a stock to compare with RVMDW →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own RVMDW, latest filings →Back to the 13F Explorer →